Articles by Jim Miller - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jim Miller

End of the Dedicated CMO?

Is the contract-only CMO an endangered species?
Mar 6, 2013

Is the contract-only CMO an endangered species?

End of the Dedicated CMO?

Is the contract-only CMO an endangered species?
Feb 2, 2013

Is the contract-only CMO an endangered species?

The State of Outsourcing Partnerships

Preferred-provider relationships are transforming the bio/pharmaceutical industry.
Feb 1, 2013

Preferred-provider relationships are transforming the bio/pharmaceutical industry.

Acquisitions Reshape the Bio/Pharm Services Industry

The quest to build critical mass and broaden capabilities has been a key factor in dealmaking.
Jan 9, 2013

The quest to build critical mass and broaden capabilities has been a key factor in dealmaking.

Acquisitions Reshape the Bio/Pharm Services Industry

The quest to build critical mass and broaden capabilities has been a key factor in deal-making.
Dec 2, 2012

The quest to build critical mass and broaden capabilities has been a key factor in deal-making.

Sizing the Market For Contract Manufacturing

Measuring the size of the market for contract manufacturing services requires a careful hand.
Nov 7, 2012

Measuring the size of the market for contract manufacturing services requires a careful hand.

The Macro View

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.
Oct 3, 2012

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.

Sizing the Market for Contract Manufacturing

Measuring the size of the market for contract manufacturing services requires a careful hand.
Oct 2, 2012

Measuring the size of the market for contract manufacturing services requires a careful hand.

The Macro View

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.
Sep 2, 2012

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
FindPharma Custom Search
Click here